# Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

> **NCT00445900** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 22 (estimated)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Secondary Myelofibrosis

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** prednisone
- **DRUG:** thalidomide
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00445900
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2011-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445900, "Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00445900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*